Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445198 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
A Phase 1 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 18
- Study locations
NCT00445198 is a Phase 1 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 86 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 18 study locations across 11 states.
The verdict
NCT00445198, a Phase 1 study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 18
- Study locations
Study Summary
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Conditions Studied
Interventions
- DRUG ABT-263
Study Locations (18)
Other
- Site Reference ID/Investigator# 7493 - Edmonton
- Site Reference ID/Investigator# 7635 - Ottawa
- Site Reference ID/Investigator# 18541 - Leicester
- Site Reference ID/Investigator# 2622 - Manchester
Arizona
- Site Reference ID/Investigator# 13605 - Peoria
- Site Reference ID/Investigator# 5261 - Phoenix
California
- Site Reference ID/Investigator# 11942 - Los Angeles
- Site Reference ID/Investigator# 4718 - Sacramento
Maryland
- Site Reference ID/Investigator# 2625 - Baltimore
- Site Reference ID/Investigator# 12343 - Bethesda
Massachusetts
- Site Reference ID/Investigator# 11941 - Boston
- Site Reference ID/Investigator# 2626 - Boston
Colorado
- Site Reference ID/Investigator# 3755 - Aurora
Georgia
- Site Reference ID/Investigator# 8324 - Atlanta
Illinois
- Site Reference ID/Investigator# 2623 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445198
The ClinicalTrials.gov registry entry for NCT00445198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (63% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABT-263 is the first listed.
NCT00445198 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00445198 about?
NCT00445198 is a clinical study titled "A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies". The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recom...
What is the current status of trial NCT00445198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2007-04. Estimated completion is 2010-12.
What conditions does trial NCT00445198 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT00445198?
The interventions under investigation include: ABT-263 (DRUG).
Who is sponsoring clinical trial NCT00445198?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00445198 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.